A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed / Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Status
Active
Cancer Type
Ewing Sarcoma
Trial Phase
Phase II
Eligibility
12 Months - 18 Years, Male and Female
Study Type
Treatment
NCD ID
NCT03441360
Protocol IDs
E7389-G000-223 (primary)
NCI-2018-00749
Study Sponsor
Eisai Inc

Summary

This study will be conducted as an assessment of the safety and preliminary activity of eribulin mesylate in pediatric participants with relapsed / refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), or Ewing sarcoma (EWS) to determine whether each cohort warrants further investigation.